神経内分泌がん治療薬の世界市場2020-2026:ソマトスタチンアナログ、標的療法、化学療法

QYResearchが発行した調査報告書(QYR20AP01586)
◆英語タイトル:Global Neuroendocrine Carcinoma Drugs Industry Research Report, Growth Trends and Competitive Analysis 2020-2026
◆商品コード:QYR20AP01586
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年3月(※2024年版があります。お問い合わせください。)
◆ページ数:110
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,087,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,450,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

当リサーチレポートでは、神経内分泌がん治療薬の世界市場規模が2019年xx百万ドルから2026年xx百万ドルまで年平均xx%成長すると予測しています。当レポートは、神経内分泌がん治療薬のグローバル市場動向、メーカー別競争状況、種類別市場規模(ソマトスタチンアナログ、標的療法、化学療法)、用途別市場規模(病院、クリニック、腫瘍学センター、外来手術センター)、北米市場、アジア市場、中南米市場、中東・アフリカ市場分析、関連企業情報、サプライチェーン、販売チャネル分析、地域別市場規模予測データなどを掲載しています。

・レポート概要
・グローバル市場動向
・メーカー別競争状況
・神経内分泌がん治療薬の種類別市場2015-2026:ソマトスタチンアナログ、標的療法、化学療法
・神経内分泌がん治療薬の用途別市場2015-2026:病院、クリニック、腫瘍学センター、外来手術センター
・神経内分泌がん治療薬の北米市場分析
・神経内分泌がん治療薬のアジア市場分析
・神経内分泌がん治療薬の中南米市場分析
・神経内分泌がん治療薬の中東・アフリカ市場分析
・関連企業情報:Xiaflex、Novartis AG、Roche、Molecular Insight pharmaceuticals、Callisto Pharmaceuticals
・サプライチェーン及び販売チャネル分析
・地域別市場規模予測2021-2026:北米、ヨーロッパ、アジア、中南米、中東・アフリカ
・結論
【レポートの概要】

In 2019, the global Neuroendocrine Carcinoma Drugs market size was US$ xx million and is forecast to US$ xx million in 2026, growing at a CAGR of xx% from 2020. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Neuroendocrine Carcinoma Drugs.The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Neuroendocrine Carcinoma Drugs market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Neuroendocrine Carcinoma Drugs market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Neuroendocrine Carcinoma Drugs market. Readers of the report can become informed about current and future trends of the global Neuroendocrine Carcinoma Drugs market and how they will impact market growth during the forecast period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise and country-wise Neuroendocrine Carcinoma Drugs markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E etc.
For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Neuroendocrine Carcinoma Drugs market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.
Market Segmentation by Type and by Application
The report includes a detailed analysis of leading and by Type and by Application segments of the global Neuroendocrine Carcinoma Drugs market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue, sales analysis and forecast of the global Neuroendocrine Carcinoma Drugs market by Type and by Application segment for the period 2015-2026.

Market Segment by Type, the Neuroendocrine Carcinoma Drugs market is segmented into
Somatostatin Analogs
Targeted Therapy
Chemotherapy

Market Segment by Application, the Neuroendocrine Carcinoma Drugs market is segmented into
Hospital
Clinics
Oncology Centres
Ambulatory Surgery Centres

This report includes the following manufacturers; we can also add the other companies as you want.
Xiaflex
Novartis AG
Roche
Molecular Insight pharmaceuticals
Callisto Pharmaceuticals

The study objectives are:
To analyze and research the global Neuroendocrine Carcinoma Drugs status and future forecast, involving capacity, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
To present the key Neuroendocrine Carcinoma Drugs manufacturers, capacity, production, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Neuroendocrine Carcinoma Drugs are as follows:
History Year: 2015-2020
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Research Scope
1.2 Top Neuroendocrine Carcinoma Drugs Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Neuroendocrine Carcinoma Drugs Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Somatostatin Analogs
1.3.3 Targeted Therapy
1.3.4 Chemotherapy
1.4 Market Segment by Application
1.4.1 Global Neuroendocrine Carcinoma Drugs Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Hospital
1.4.3 Clinics
1.4.4 Oncology Centres
1.4.5 Ambulatory Surgery Centres
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Neuroendocrine Carcinoma Drugs Revenue (2015-2026)
2.1.1 Global Neuroendocrine Carcinoma Drugs Revenue (2015-2026)
2.1.2 Global Neuroendocrine Carcinoma Drugs Sales (2015-2026)
2.2 Neuroendocrine Carcinoma Drugs Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Neuroendocrine Carcinoma Drugs Sales by Regions (2015-2020)
2.2.2 Global Neuroendocrine Carcinoma Drugs Revenue by Regions (2015-2020)
2.3 Global Top Neuroendocrine Carcinoma Drugs Regions (Countries) Ranking by Market Size
2.4 Neuroendocrine Carcinoma Drugs Industry Trends
2.4.1 Neuroendocrine Carcinoma Drugs Market Top Trends
2.4.2 Market Drivers
2.4.3 Neuroendocrine Carcinoma Drugs Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Neuroendocrine Carcinoma Drugs Players: Views for Future

3 Competitive Landscape by Manufacturers
3.1 Global Top Neuroendocrine Carcinoma Drugs Manufacturers by Sales (2015-2020)
3.1.1 Global Neuroendocrine Carcinoma Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Neuroendocrine Carcinoma Drugs Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Neuroendocrine Carcinoma Drugs Sales in 2019
3.2 Global Top Manufacturers Neuroendocrine Carcinoma Drugs by Revenue
3.2.1 Global Neuroendocrine Carcinoma Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Neuroendocrine Carcinoma Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neuroendocrine Carcinoma Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma Drugs as of 2019)
3.4 Global Neuroendocrine Carcinoma Drugs Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Neuroendocrine Carcinoma Drugs Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Neuroendocrine Carcinoma Drugs Market
3.7 Key Manufacturers Neuroendocrine Carcinoma Drugs Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Neuroendocrine Carcinoma Drugs Historic Market Review by Type (2015-2020)
4.1.2 Global Neuroendocrine Carcinoma Drugs Sales Market Share by Type (2015-2020)
4.1.3 Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Type (2015-2020)
4.1.4 Neuroendocrine Carcinoma Drugs Price by Type (2015-2020)
4.1 Global Neuroendocrine Carcinoma Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Neuroendocrine Carcinoma Drugs Sales Forecast by Type (2021-2026)
4.2.3 Global Neuroendocrine Carcinoma Drugs Revenue Forecast by Type (2021-2026)
4.2.4 Neuroendocrine Carcinoma Drugs Price Forecast by Type (2021-2026)

5 Global Neuroendocrine Carcinoma Drugs Market Size by Application
5.1 Global Neuroendocrine Carcinoma Drugs Historic Market Review by Application (2015-2020)
5.1.2 Global Neuroendocrine Carcinoma Drugs Sales Market Share by Application (2015-2020)
5.1.3 Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Application (2015-2020)
5.1.4 Neuroendocrine Carcinoma Drugs Price by Application (2015-2020)
5.2 Global Neuroendocrine Carcinoma Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Neuroendocrine Carcinoma Drugs Sales Forecast by Application (2021-2026)
5.2.3 Global Neuroendocrine Carcinoma Drugs Revenue Forecast by Application (2021-2026)
5.2.4 Neuroendocrine Carcinoma Drugs Price Forecast by Application (2021-2026)

6 North America
6.1 North America Neuroendocrine Carcinoma Drugs Breakdown Data by Company
6.2 North America Neuroendocrine Carcinoma Drugs Breakdown Data by Type
6.3 North America Neuroendocrine Carcinoma Drugs Breakdown Data by Application
6.4 North America Neuroendocrine Carcinoma Drugs Breakdown Data by Countries
6.4.1 North America Neuroendocrine Carcinoma Drugs Sales by Countries
6.4.2 North America Neuroendocrine Carcinoma Drugs Revenue by Countries
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe Neuroendocrine Carcinoma Drugs Breakdown Data by Company
7.2 Europe Neuroendocrine Carcinoma Drugs Breakdown Data by Type
7.3 Europe Neuroendocrine Carcinoma Drugs Breakdown Data by Application
7.4 Europe Neuroendocrine Carcinoma Drugs Breakdown Data by Countries
7.4.1 Europe Neuroendocrine Carcinoma Drugs Sales by Countries
7.4.2 Europe Neuroendocrine Carcinoma Drugs Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific Neuroendocrine Carcinoma Drugs Breakdown Data by Company
8.2 Asia Pacific Neuroendocrine Carcinoma Drugs Breakdown Data by Type
8.3 Asia Pacific Neuroendocrine Carcinoma Drugs Breakdown Data by Application
8.4 Asia Pacific Neuroendocrine Carcinoma Drugs Breakdown Data by Regions
8.4.1 Asia Pacific Neuroendocrine Carcinoma Drugs Sales by Regions
8.4.2 Asia Pacific Neuroendocrine Carcinoma Drugs Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America Neuroendocrine Carcinoma Drugs Breakdown Data by Company
9.2 Latin America Neuroendocrine Carcinoma Drugs Breakdown Data by Type
9.3 Latin America Neuroendocrine Carcinoma Drugs Breakdown Data by Application
9.4 Latin America Neuroendocrine Carcinoma Drugs Breakdown Data by Countries
9.4.1 Latin America Neuroendocrine Carcinoma Drugs Sales by Countries
9.4.2 Latin America Neuroendocrine Carcinoma Drugs Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Neuroendocrine Carcinoma Drugs Breakdown Data by Type
10.2 Middle East and Africa Neuroendocrine Carcinoma Drugs Breakdown Data by Application
10.3 Middle East and Africa Neuroendocrine Carcinoma Drugs Breakdown Data by Countries
10.3.1 Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Countries
10.3.2 Middle East and Africa Neuroendocrine Carcinoma Drugs Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E

11 Company Profiles
11.1 Xiaflex
11.1.1 Xiaflex Corporation Information
11.1.2 Xiaflex Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Xiaflex Neuroendocrine Carcinoma Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Xiaflex Neuroendocrine Carcinoma Drugs Products and Services
11.1.5 Xiaflex SWOT Analysis
11.1.6 Xiaflex Recent Developments
11.2 Novartis AG
11.2.1 Novartis AG Corporation Information
11.2.2 Novartis AG Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Novartis AG Neuroendocrine Carcinoma Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Novartis AG Neuroendocrine Carcinoma Drugs Products and Services
11.2.5 Novartis AG SWOT Analysis
11.2.6 Novartis AG Recent Developments
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Business Overview and Total Revenue (2019 VS 2018)
11.3.3 Roche Neuroendocrine Carcinoma Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 Roche Neuroendocrine Carcinoma Drugs Products and Services
11.3.5 Roche SWOT Analysis
11.3.6 Roche Recent Developments
11.4 Molecular Insight pharmaceuticals
11.4.1 Molecular Insight pharmaceuticals Corporation Information
11.4.2 Molecular Insight pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Products and Services
11.4.5 Molecular Insight pharmaceuticals SWOT Analysis
11.4.6 Molecular Insight pharmaceuticals Recent Developments
11.5 Callisto Pharmaceuticals
11.5.1 Callisto Pharmaceuticals Corporation Information
11.5.2 Callisto Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Products and Services
11.5.5 Callisto Pharmaceuticals SWOT Analysis
11.5.6 Callisto Pharmaceuticals Recent Developments

12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Neuroendocrine Carcinoma Drugs Sales Channels
12.2.2 Neuroendocrine Carcinoma Drugs Distributors
12.3 Neuroendocrine Carcinoma Drugs Customers

13 Estimates and Projections by Regions (2021-2026)
13.1 Global Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
13.1.1 Global Neuroendocrine Carcinoma Drugs Sales Forecast by Regions (2021-2026)
13.1.2 Global Neuroendocrine Carcinoma Drugs Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
13.2.2 North America Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
13.2.3 North America Neuroendocrine Carcinoma Drugs Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
13.3.2 Europe Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
13.3.3 Europe Neuroendocrine Carcinoma Drugs Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
13.4.2 Asia Pacific Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Neuroendocrine Carcinoma Drugs Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
13.5.2 Latin America Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
13.5.3 Latin America Neuroendocrine Carcinoma Drugs Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Neuroendocrine Carcinoma Drugs Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Neuroendocrine Carcinoma Drugs Size Forecast by County (2021-2026)

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

...

【掲載企業】

Xiaflex、Novartis AG、Roche、Molecular Insight pharmaceuticals、Callisto Pharmaceuticals

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 神経内分泌がん治療薬の世界市場2020-2026:ソマトスタチンアナログ、標的療法、化学療法(Global Neuroendocrine Carcinoma Drugs Industry Research Report, Growth Trends and Competitive Analysis 2020-2026)]についてメールでお問い合わせはこちらでお願いします。